secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066403
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q1 net loss $114.3M, cash $707.1M; Phase 3 HAE enrollment on track
---------------------------------------------------------------------------

- Net loss $114.3M vs $107.4M in Q1 2024; collaboration revenue $16.6M down from $28.9M.
- Cash, cash equivalents and marketable securities $707.1M as of March 31, 2025, down from $861.7M at Dec 31, 2024; expected to fund operations into H1 2027.
- Phase 3 HAELO study for hereditary angioedema on track to complete enrollment in Q3 2025; BLA submission anticipated in H2 2026.
- First patient dosed in Phase 3 MAGNITUDE-2 for ATTRv-PN; MAGNITUDE (ATTR-CM) enrollment ahead of projections.
- RMAT designation granted for nex-z in ATTR-CM; longer-term Phase 1 data presentations planned for H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/0000950170-25-066403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017025066403/ntla-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer